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ABSTRACT
Background Cardiovascular disease (CVD) inﬂuences
phenotypic variation in Parkinson’s disease (PD), and is
usually an indication for statin therapy. It is less clear
whether cardiovascular risk factors inﬂuence PD
phenotype, and if statins are prescribed appropriately.
Objectives To quantify vascular risk and statin use in
recent-onset PD, and examine the relationship between
vascular risk, PD severity and phenotype.
Methods Cardiovascular risk was quantiﬁed using the
QRISK2 calculator (high ≥20%, medium ≥10 and
<20%, low risk <10%). Motor severity and phenotype
were assessed using the Movement Disorder Society
Uniﬁed PD Rating Scale (UPDRS) and cognition by the
Montreal cognitive assessment.
Results In 2909 individuals with recent-onset PD, the
mean age was 67.5 years (SD 9.3), 63.5% were men
and the mean disease duration was 1.3 years (SD 0.9).
33.8% of cases had high vascular risk, 28.7% medium
risk, and 22.3% low risk, while 15.2% of cases had
established CVD. Increasing vascular risk and CVD were
associated with older age (p<0.001), worse motor score
(p<0.001), more cognitive impairment (p<0.001) and
worse motor phenotype (p=0.021). Statins were
prescribed in 37.2% with high vascular risk, 15.1% with
medium vascular risk and 6.5% with low vascular risk,
which compared with statin usage in 75.3% of those
with CVD.
Conclusions Over 60% of recent-onset PD patients
have high or medium cardiovascular risk (meriting statin
usage), which is associated with a worse motor and
cognitive phenotype. Statins are underused in these
patients, compared with those with vascular disease,
which is a missed opportunity for preventive treatment.
Trial registration number GN11NE062, NCT02881099.
BACKGROUND
Parkinson’s disease (PD) and cardiovascular disease
(CVD) become more prevalent with advancing age.
CVD is therefore likely to affect a large number of
individuals with PD. A variety of clinical, imaging
and pathological studies in elderly individuals
without PD,1 2 as well as smaller PD studies,3–10
show links between established vascular disease and
vascular risk factors, and gait and cognitive impair-
ment. A combination of Lewy body and vascular
pathology may create a mixed clinical phenotype,
and explain some of the variation in the responsive-
ness of the motor and cognitive features to antipar-
kinsonian therapy.
Vascular preventive treatment is well established.
Primary prevention is recommended when an indi-
vidual’s calculated 10-year vascular risk is 10% or
more11 and involves the use of cholesterol-lowering
therapy (mainly with HMG-CoA reductase inhibi-
tors, commonly referred to as statins) and manage-
ment of other vascular risk factors such as
hypertension. Secondary prevention (after a vascu-
lar event) similarly involves the use of statins, as
well as antihypertensive and antiplatelet therapy.
Additionally, statins are of particular interest in PD
as possible neuroprotectants, given their beneﬁcial
role in the attenuation of inﬂammatory responses,
including the production of tumour necrosis factor
α, nitric oxide and superoxide; the reduction in the
accumulation of α-synuclein; and alteration of
dopamine D1/D2 receptor modulation.12 However,
varying rates of statin usage are reported in patients
with vascular risk and vascular disease,13–18 and it
is not known whether PD patients have equitable
access to statins.
We therefore studied cardiovascular risk and
CVD rates in recent-onset PD, in relation to clinical
phenotype, more speciﬁcally the motor and cogni-
tive features, and the use of statins in these patients.
METHODS
Participants
Study participants were enrolled prospectively in
either the UK Tracking Parkinson’s study, or the
Oxford Discovery study. Participants were recruited
from February 2012 to May 2014 in the Tracking
Parkinson’s study and from September 2010 to
October 2015 in the Oxford Discovery study. Our
analysis is based on the baseline data from these
large multicentre studies, whose protocols includ-
ing inclusion/exclusion criteria are detailed else-
where.19 20 In brief, in both studies, cases with a
clinical diagnosis of PD were recruited, fulﬁlling
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Queen Square Brain Bank criteria, with written consent,
approval of multicentre regional ethics committees and in com-
pliance with national legislation and the Declaration of
Helsinki. For the current analysis, cases with normal functional
dopaminergic imaging performed after study entry, and cases
with a revised diagnosis at their latest follow-up visit, were
excluded. When assessing the clinical correlates of CVD, we
further excluded cases with any features that were possibly atyp-
ical or unusual at baseline assessment, including an unusual
presentation, symptom, sign, progression or response to medica-
tion, to reduce any effect from a possible alternative diagnosis
than PD (eg, vascular parkinsonism).
Measurement instruments
Established vascular diagnoses and risk factors were collected
from self-report completed at clinic attendance, and was per-
formed at the same time as, and therefore with input from,
physician/nurse access to medical records. The individual vascu-
lar factors collected are the standard risk factor variables recom-
mended by the National Institute of Clinical Excellence (NICE)
in the UK to clinically assess vascular risk.21 The 10-year future
cardiovascular risk was then calculated using the QRISK2-2015
prediction algorithm,22 also recommended by NICE,11 which
computes risk based on demographic and comorbid vascular
features for example, age, smoking status, ethnicity, systolic
blood pressure, body mass index, treated hypertension and type
2 diabetes. The calculation is only appropriate in patients aged
under 85 years and without a previous vascular event. Since
national treatment thresholds were reduced recently from 20%
to 10% calculated risk,11 statin implementation was examined
against both of these thresholds, and designated as high
(≥20%), medium (≥10 and <20%) or low (<10%) risk.
Vascular preventive medications, including lipid-lowering, anti-
platelet, anticoagulant and antihypertensive therapies, were
identiﬁed from medication histories, using British National
Formulary classiﬁcations.
Motor function was scored according to Part 3 of the
Movement Disorder Society Uniﬁed PD Rating Scale
(UPDRS 3), and was used to deﬁne motor subtype using a
predetermined formula which uses these variables to deﬁne
tremor dominant (TD) and postural instability gait difﬁculty
(PIGD) phenotypes.23 Cognition was assessed by the Montreal
cognitive assessment (MoCA), adjusted for education years
according to standard methods (1 point added to the total score
if education years were ≤12, to a maximum score of 30) and
categorised as normal cognition (24–30), mild cognitive impair-
ment (22–23) or dementia (<22).24 Levodopa equivalent daily
dose (LEDD) was calculated using an established formula.25
Statistical analysis
Generalised linear modelling was used to assess clinical variables
across vascular risk categories, adjusting for multiple covariates
(age, sex, disease duration and coffee use), with heterogeneity
and trend p values calculated when there were more than two
categories. The linearity of the continuous confounders (age
and disease duration) was tested using fractional polynomials in
univariate models and then transformed if they showed evidence
of non-linearity. Regression models used were: multinomial
logistic for motor subtype analysis (using TD as the baseline);
ordered logistic for categorised MoCA and smoking status;
linear for age, disease duration, MoCA total, LEDD and UPDRS
3; and logistic for sex. The main analysis excluded those with a
revised diagnosis, those diagnosed >3.5 years ago and those
without available QRISK2 prediction algorithm or medication
data. An additional sensitivity analysis was performed imputing
missing outcome and exposure data. In this analysis, MoCA,
motor phenotype and UPDRS 3 scores were calculated using
expected scores where at least 80% of the questions in each
scale were answered. Any remaining missing data were imputed
using the chained equation approach to multiple imputation,
creating 10 imputed data sets. Adjusted p values of <0.05 were
considered signiﬁcant. IBM SPSS Statistics for Windows, V.22.0,
Armonk, New York, USA, and STATAV.13 were used.
RESULTS
Out of 3019 cases (Tracking Parkinson’s 2006, Oxford
Discovery 1013), 110 (3.6%) were excluded for the following
reasons: revised diagnosis (n=32), disease duration >3.5 years
(n=49), missing statin usage (n=5) and missing QRISK2 status
(n=24; ﬁgure 1). In the remaining 2909 cases, the mean age
was 67.5 years (SD 9.3), mean disease duration 1.3 years (SD
0.9) and 65.3% were men. Further baseline characteristics are
summarised in table 1.
Established vascular disease was present in 15.2% of cases
(table 2). Hypertension was present in 34.4%, high cholesterol
in 32.4%, diabetes in 8.6% and current cigarette smoking in
3.2%. Antihypertensive medication was the most commonly
prescribed preventive cardiovascular therapy at 39.5%, while
lipid-lowering medication was prescribed in 30.4%. Statins were
the most common lipid-lowering medication (97.9% of cases on
lipid-lowering therapy). Other cardiovascular risk factors and
preventive medications are listed in table 2.
The QRISK2 score (ie, 10-year future cardiovascular risk) was
low in 648 cases (22.3%), medium in 836 cases (28.7%) and
high in 984 cases (33.8%; table 3). Statins were prescribed in a
minority of those with a vascular risk indication for their use
(15.1% of those with medium vascular risk, and 37.2% of cases
with high vascular risk). In contrast, statins were prescribed in
75.3% of cases with established vascular disease.
The relationship between graded vascular risk and vascular
disease, and the clinical characteristics of PD was analysed in
the 2611 cases without any features that might possibly indicate
Figure 1 Disposition of cases recruited to the study, and reasons for
exclusion. The main analysis was performed in 2909 cases; clinical
correlates were examined in 2611 cases, to reduce any effect of
possible diagnostic inaccuracy. PD, Parkinson’s disease, PSP, progressive
supra nuclear palsy, MSA, multiple system atrophy.
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an alternative diagnosis than PD (table 4). This meant that 298
cases were excluded from this analysis (10.2% of the 2909
study group). The analysis also excluded cases with missing
results for disease duration (n=6, 0.2%), UPDRS 3 (n=189,
7.2%), motor subtype (n=185, 7.1%), MoCA (n=157, 6.0%)
and LEDD (n=20, 0.8%). Additional analysis using multiple
imputation of this missing data showed no qualitative differ-
ences, aside from the LEDD comparison in statin versus non-
statin users (results not shown).
Increasing vascular risk was associated with increasing age
(p<0.001) and an increasing proportion of men (p<0.001).
Increasing vascular risk was also associated with worsening
UPDRS 3 scores when adjusted for age, sex, disease duration
and coffee intake (p<0.001), with UPDRS 3 scores ranging
from 20.3 (SD 10.7) in those with a low QRISK2 score to 26.8
(SD 12.3) in those with established vascular disease. Increasing
vascular risk was similarly associated with an increasing propor-
tion with the PIGD phenotype (p=0.021) rising from 32.3% in
those with a low QRISK2 score to 48.0% of cases with estab-
lished vascular disease. Increasing vascular risk was also asso-
ciated with increasing cognitive impairment; a worsening
MoCA score (p<0.001) as well as an increasing proportion
with MCI and dementia (p=0.008). The motor and cognitive
characteristics of cases with high vascular risk were very similar
to those seen in cases with established vascular disease (table 4).
When we considered the potential effects of the interaction of
sex on the clinical correlates of each vascular risk category, we
did not ﬁnd any statistically signiﬁcant interactions (data not
shown).
When we compared the clinical features of individuals treated
versus untreated with statins (all indications), statin users had
less PIGD (p=0.002) but a lower total MoCA score (p<0.001)
and a greater proportion with cognitive impairment (p=0.010).
Statin users also had a greater LEDD (p=0.035), but, as
described earlier, this was not signiﬁcant in our multiple imput-
ation analysis (table 5).
Table 2 Vascular disease, risk factors and treatment in 2909
recent-onset Parkinson’s disease cases
Variable Result
Vascular diagnosis 441 (15.2%)
Angina 269 (9.3%)
Myocardial infarction 134 (4.6%)
Transient ischaemic attack/stroke 150 (5.2%)
Vascular risk factors
Diabetes 249 (8.6%)
Type 1 13 (0.5%)
Type 2 236 (8.2%)
High cholesterol 936 (32.4%)
Hypertension 992 (34.4%)
Rheumatoid arthritis 69 (2.4%)
Body mass index (kg/m2) 27.1 (4.7)
Blood pressure, systolic/diastolic 140 (20)/80 (11)
Orthostatic hypotension 525 (18.5%)
Smoking
Non-smoker 1539 (57.9%)
Ex-smoker 1023 (38.5%)
Current smoker 96 (3.2%)
Light 48 (1.8%)
Moderate 33 (1.3%)
Heavy 15 (0.6%)
Current coffee intake (cups per day)
Less than 1 257 (9.6%)
1 194 (7.2%)
2–3 719 (26.7%)
4 or more 1522 (56.5%)
Cardiovascular medication
Lipid lowering 885 (30.4%)
Statins 866 (97.9%)*
Other 19 (2.1%)*
Antihypertensive 1150 (39.5%)
Antiplatelet 430 (14.8%)
Anticoagulant 122 (4.2%)
*Percentage of total lipid lowering.
Data are mean (SD) or number (percentage).
Table 3 Vascular preventive medication usage according to
indication in 2909 recent-onset Parkinson’s disease cases
Medication
Primary prevention
Secondary
prevention
QRISK2
<10%
=648
(22.3%)
QRISK2
≥10% and
<20%
n=836
(28.7%)
QRISK2
≥20%
n=984
(33.8%)
n=441
(15.2%)
Statin 42 (6.5%) 126 (15.1%) 366 (37.2%) 332 (75.3%)
Antihypertensive 96 (14.8%) 236 (28.2%) 533 (54.2%) 345 (78.2%)
Antiplatelet/
anticoagulant
15 (2.3%) 69 (8.3%) 180 (18.3%) 279 (63.3%)
Data are number (percentage). QRISK2 is the 10-year future calculated cardiovascular
risk.
Table 1 Demographic and clinical characteristics of 2909
recent-onset Parkinson’s disease cases
Variable Result
Age 67.5 (9.3)
Male sex 1898 (65.3%)
Disease duration (years) 1.3 (0.9)
UPDRS 3 24.2 (12.1)
Motor subtype
TD 1303 (48.1%)
PIGD 1061 (39.2%)
Indeterminate 344 (12.7%)
MoCA
Total score 25.1 (3.5)
Normal 1972 (72.1%)
MCI 370 (13.5%)
Dementia 394 (14.4%)
Antiparkinsonian medication
Drug naïve 314 (10.8%)
Levodopa 1776 (61.2%)
Dopamine agonist 873 (30.0%)
MAOB inhibitor 723 (24.9%)
COMT inhibitor 67 (2.3%)
Anticholinergic 38 (1.3%)
Amantadine 28 (1.0%)
LEDD 292 (214)
Data are mean (SD) or number (percentage).
COMT, catechol-O-methyl transferase; LEDD, levodopa equivalent daily dose; MAOB,
monoamine oxidase type B; MCI, mild cognitive impairment; MoCA, Montreal
cognitive assessment; PIGD, postural instability gait difficulty; TD, tremor dominant;
UPDRS 3, Movement Disorder Society unified Parkinson’s disease rating scale part 3.
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When we compared the clinical features of those using and
not using statins in individuals with established vascular disease
and a QRISK2 score ≥10% (table 6), those treated with statins
in the QRISK2 ≥10% subgroup had less PIGD (p=0.009), but
also lower total MoCA scores and a greater proportion with
cognitive impairment (p<0.001). Conversely in those with
established CVD, those treated with statins were better cogni-
tively, but with no signiﬁcant differences in the proportion with
PIGD.
DISCUSSION
We have found, in a large study of recent-onset PD, that over
60% of cases have increased cardiovascular risk (without a
history of vascular disease) that places them in a recommended
treatment category for statin therapy. However, only around a
quarter of those cases (27.0%) were prescribed such therapy. In
contrast, fewer patients (around 15%) have manifest CVD, but
a much larger proportion of these cases (75.3%) are prescribed
statins. Given that statins are indicated in both groups,11 the
comparatively lower usage of statins in those with increased vas-
cular risk, compared with those with manifest CVD, suggests
that the assessment and/or treatment approach to vascular risk
is fundamentally different from that of manifest vascular
disease, in recent-onset PD patients. The clinical relevance of
this is suggested by the signiﬁcant association of vascular risk,
in addition to established CVD, with greater motor severity,
including more axial features and gait problems, and with cog-
nitive problems, including mild cognitive impairment and
dementia.
The effects we have observed relating vascular risk to clinical
phenotype in PD extend the evidence linking vascular risk
factors with worse neurological status in prior smaller studies.
PD cases with diabetes had worse global cognition,5 greater
axial impairment6 and more rapid progression in terms of
motor scores,7 while PD cases with hypertension had worse
executive function and delayed memory.4 Further, carotid artery
intima-medial thickness (a marker of subclinical vascular
disease) correlated with higher levels of motor and cognitive
impairment;26 and the presence of one or more vascular risk
factor was associated with greater cognitive impairment and
motor severity.27 Similar observations relate vascular risk to
worse neurological status in Alzheimer’s disease (AD)28 and
multiple sclerosis,29 so these effects in PD are not unique.
Our use of a combined cardiovascular risk assessment tool is
the subject of only one other PD study30 31 to the best of our
knowledge, which used a simpliﬁed version of the Framingham
risk score. In that study, in 61 cases with an elevated
Framingham risk, the Timed Up and Go test was signiﬁcantly
slower than in 22 cases with normal scores,30 and increased
Framingham scores correlated with the axial motor impair-
ment,31 again in keeping with the relationship between vascular
risk and motor pattern in our study. Unlike the current study
however, they found no relationship between vascular risk and
motor or cognitive scoring, perhaps because of their longer PD
duration (5.5 years) and considerably smaller study size.30
Considering dopaminergic therapy, one recent study found that
PD cases with preceding diabetes were prescribed larger doses
than cases without preceding diabetes.32 We did not ﬁnd any
association between LEDD and vascular risk, even after adjust-
ment for patient age (which may inﬂuence drug dosage), despite
their greater motor severity. We plan to test whether this is asso-
ciated with lesser dopaminergic responsiveness in patients with
vascular risk, in the ongoing follow-up phase of our study,
which includes formal measurement of the L-dopa response.
Table 4 Clinical correlates in 2611 recent-onset Parkinson’s disease cases according to the presence of future cardiovascular risk and existing
cardiovascular disease
Variable
QRISK2
<10%
n=590 (22.6%)
QRISK2
≥10% and <20%
n=760 (29.1%)
QRISK2
≥20%
n=886 (33.9%)
Vascular disease
n=375 (14.4%) Unadjusted p value Adjusted p value
Age 55.9 (7.0) 65.9 (4.5) 74.2 (5.3) 72.4 (7.6) <0.001 <0.001*
Male sex 233 (39.5%) 482 (63.4%) 698 (78.8%) 284 (75.7%) <0.001 <0.001†
Disease duration 1.3 (0.9) 1.3 (0.9) 1.3 (0.9) 1.4 (0.9) 0.05 0.78‡
UPDRS 3 20.3 (10.7) 22.2 (10.9) 25.9 (12.1) 26.8 (12.3) <0.001 <0.001§
Motor subtype
TD 299 (54.6%) 363 (51.0%) 397 (48.2%) 137 (40.1%)
PIGD 177 (32.3%) 248 (34.8%) 330 (40.0%) 164 (48.0%) <0.001 0.021§
Indeterminate 72 (13.1%) 101(14.2%) 97 (11.8%) 41 (12.0%) 0.60 0.069§
MoCA
Total score 26.6 (2.7) 25.6 (3.2) 24.2 (3.6) 24.1 (3.5) <0.001 <0.001§
Normal 486 (88.0%) 569 (79.7%) 511 (61.6%) 216 (60.3%) <0.001 0.008§
MCI 38 (6.9%) 77 (10.8%) 147 (17.7%) 64 (17.9%)
Dementia 28 (5.1%) 68 (9.5%) 172 (20.7%) 78 (21.8%)
LEDD 273 (215) 287 (222) 291 (190) 314 (202) 0.004 0.069§
Smoking <0.001 <0.001§
Non-smoker 413 (76.3%) 415 (58.9%) 411 (50.4%) 158 (47.7%)
Ex-smoker 108 (20.0%) 265 (37.6%) 375 (46.0%) 160 (48.3%)
Current smoker 20 (3.7%) 25 (3.5%) 30 (3.7%) 13 (3.9%)
Data are mean (SD) or number (percentage) unless otherwise stated.
*Adjusted for disease duration and sex.
†Adjusted for age and disease duration.
‡Adjusted for age and sex.
§Adjusted for age, sex, disease duration and coffee intake.
LEDD, levodopa equivalent daily dose; MCI, mild cognitive impairment; MoCA, Montreal cognitive assessment; PIGD, postural instability gait difficulty; TD, tremor dominant; UPDRS 3,
Movement Disorder Society unified Parkinson’s disease rating scale part 3.
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The usage of statins in PD can be compared with that in
other patient groups, although there are differences in method-
ology between the studies. In UK primary care, 80% of high
vascular risk cases (Framingham score >20%) were treated with
statins, which is more than double the 37.2% rate in our PD
cases with similar risk (QRISK2 ≥20%). However, in that study,
only 43% of individuals had a calculable vascular risk, and the
80% proportion on statins refers to this subset of cases and is
therefore artiﬁcially high.13 In a Swiss study, lipid-lowering
therapy was prescribed in 71% of high-risk cases, although this
included a mix of cases with established CVD and high vascular
risk scores.18 That study also described a medium-risk group
(10–20% vascular risk), of whom 48% were prescribed statins,
much higher than our rate of 15.1% for a comparable risk level.
Although based on disease markers rather than calculated risk,
higher statin usage was also reported in a European cross-
sectional study: 42.2% with diabetes and 47.0% with high
cholesterol.16
The rate of statin use in our PD cases with established CVD
(75.3%) is very similar to the 74% rate of statin use for compar-
able cases in UK primary care,13 and higher than that observed
in other settings: 68.6% of Irish community-living adults,17 and
43.4% of Italian patients after myocardial infarction.15
Overall, there appear to be higher rates of statin use in cases
with manifest CVD than cases with increased vascular risk,
which matches our ﬁndings in PD cases. Some more speciﬁc PD
factors may inﬂuence this pattern. First, it is possible that the
low cigarette smoking rate in PD cases may mislead the patient
or clinician when considering vascular risk. Second, muscle
cramps are a recognised barrier to statin use and occur in 5% of
the general population,33 but may be contributed by PD symp-
toms; there may be a lower tolerance to statins in patients with
such symptoms and increased vascular risk, compared with those
with manifest CVD. Preliminary ﬁndings from the Parkinson’s
Pain Study suggest that around 13% of early PD patients experi-
ence painful cramps (Dr Monty Silverdale, personal communica-
tion) which may affect statin use. Although the complexity of
many antiparkinsonian drug regimens, and other comorbidities,
can lead to a high pill burden, which is known to affect medica-
tion usage, this does not readily explain the differences in statin
use comparing our vascular risk and CVD cases. It may be that,
in the absence of manifest CVD, clinicians primarily focus on
PD rather than considering opportunistic vascular preventive
treatments. Further analysis of reasons for the non-
implementation or early cessation of statins in PD was beyond
the scope of the current project, but merits speciﬁc study.
The potential implications of undertreating vascular risk in PD
require consideration. If vascular risk is undertreated in PD as a
result of statin underutilisation, this could inﬂuence the fre-
quency of vascular disease seen in a PD population, which may
explain some of the variability in studies comparing the fre-
quency of CVD and risk factors in PD and controls. This could
in turn inﬂuence conclusions relating to the aetiological role of
vascular disease in PD. Vascular preventive therapy primarily
reduces acute vascular events, for example, stroke and myocar-
dial infarction,11 but may also limit chronic vascular damage.
Following stroke, statins reduced white matter hyperintensity
progression rates, and limited the decline in executive func-
tion.34 In AD, observational data suggested that treating vascular
risk factors altered the rate of cognitive decline, although one
can argue such studies are subject to bias.35 Improving the imple-
mentation of such treatments may therefore limit a vascular com-
ponent of motor and cognitive deterioration in PD. However,
there are limited data on such effects in PD. In one study, the
presence of hypertension in PD patients correlated with greater
Hoehn and Yahr stage progression over 5 years.27 In the ongoing
follow-up phase of our study, we will test whether vascular risk
and vascular disease contribute to the evolution of phenotype
from TD to PIGD found in earlier longitudinal PD studies.36
The observation that individuals with the same vascular risk,
but who were treated with statins, had a smaller proportion
with the PIGD phenotype than those untreated with statins may
lend support to the potential beneﬁts of treating established
CVD and elevated cardiovascular risk in PD. However, in those
with a QRISK2 score ≥10%, those treated with statins had
more cognitive impairment compared with those who were
untreated. One possible explanation for this is a positive selec-
tion bias for starting statins, or maintaining them, when cogni-
tion is more impaired, or risks are perceived to be greater (such
as in men). Although there are potential mechanisms whereby
statins might increase cognitive impairment (through interfer-
ence with myelin formation and function,37 and reduction in
coenzyme-Q10 levels leading to impaired mitochondrial func-
tioning and increased oxidative stress38), a recent systematic
review and meta-analysis did not ﬁnd any evidence of signiﬁcant
adverse effects of statins on cognition, either in cognitively
normal participants or in those with AD.39 In addition, a
reverse effect was seen in our study in those with established
vascular disease, where those not using statins were cognitively
worse. Given that our study is observational, we cannot reach
deﬁnite conclusions and therefore the results of the Simvastatin
as a Neuroprotective Treatment for Moderate Parkinson’s
Disease (PD STAT) randomised placebo-controlled trial will be
Table 5 Clinical correlates in 2611 recent-onset Parkinson’s
disease cases according to the use of statin medication
Variable
Statin use,
n=769
No statin
use, n=1842
Unadjusted
p value
Adjusted
p value
Age 71.1 (7.4) 65.8 (9.4) <0.001 0.16*
Sex 573 (74.5%) 1124 (61.0%) <0.001 0.52†
Disease duration 1.3 (0.9) 1.3 (0.9) 0.34 0.96‡
UPDRS 3 25.3 (11.9) 23.0 (11.6) <0.001 0.97§
Motor subtype
TD 361 (50.1%) 835 (49.0%)
PIGD 268 (37.2%) 651 (38.2%) 0.61 0.002§
Mixed 92 (12.8%) 219 (12.8%) 0.84 0.75§
MoCA
Total 24.2 (3.7) 25.5 (3.3) <0.001 <0.001§
Normal 450 (62.2%) 1332 (76.9%) <0.001 0.010§
MCI 120 (16.6%) 206 (11.9%)
Dementia 153 (21.2%) 193 (11.1%)
LEDD 291 (209) 288 (207) 0.71 0.035§
Smoking
Non-smoker 352 (50.7%) 1045 (61.5%) <0.001 0.82§
Ex-smoker 319 (46.0%) 589 (34.7%)
Current smoker 23 (3.3%) 65 (3.8%)
Data are mean (SD) or number (percentage) unless otherwise stated.
*Adjusted for disease duration, sex and presence of existing cardiovascular disease or
future cardiovascular risk.
†Adjusted for age, disease duration and presence of existing cardiovascular disease or
future cardiovascular risk.
‡Adjusted for age, sex and presence of existing cardiovascular disease or future
cardiovascular risk.
§Adjusted for age, sex, disease duration, coffee use and presence of existing
cardiovascular disease or future cardiovascular risk.
MCI, mild cognitive impairment; MoCA, Montreal cognitive assessment; PIGD,
postural instability gait difficulty; TD, tremor dominant; UPDRS3, Movement Disorder
Society unified Parkinson’s disease rating scale part 3.
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of major importance (ClinicalTrials.gov identiﬁer
NCT02787590).
One limitation of our study is that the NICE guideline thresh-
old was amended (from QRISK2 ≥20% to QRISK2 ≥10%) in
July 2014,11 which overlapped with our study recruitment. For
this reason, we stratiﬁed our results by the prior 20% threshold
(published in 2008) and the newer 10% threshold. However,
even considering the 20% threshold (37.2% prescribed statins),
there was a major difference in statin use compared with that in
manifest CVD (75.3% prescribed statins). A further limitation
of the current study is that neuroimaging (eg, MRI or CT) was
not used to assess vascular changes. While we have explored
imaging in relation to individual risk factors elsewhere, our
desired focus within this study was on the clinical assessment of
vascular risk. We did not record statin dosage information, but
this is in keeping with many studies which have explored statin
use according to vascular risk indication,13 16 17 and with many
studies examining statin use in relation to the risk of PD.40 A
ﬁnal limitation of our study relates to diagnostic accuracy, which
like other early PD studies was based on clinical diagnosis in a
research framework using clinical diagnostic criteria. Although
some cases may evolve to an alternative diagnosis, in most cases,
vascular risk assessment and appropriately directed treatment
remain relevant. For this reason, we included all patients in our
assessment of vascular risk and treatment, and limited our ana-
lysis to patients without possible atypical features only when
examining clinical correlates between vascular risk and disease,
and PD phenotype.
In conclusion, a large proportion of individuals with
recent-onset PD have increased cardiovascular risk, which is
associated with greater motor and cognitive severity, and greater
axial impairment. Statin therapy is underused in these PD cases,
which contrasts with much high rates of statin use in PD cases
with manifest CVD. Increasing the usage of statins in PD
patients with increased vascular risk would reduce acute cardio-
vascular events, but might also reduce chronic vascular damage,
and thereby slow the progression of motor and cognitive
decline. Patients with PD have regular visits to healthcare provi-
ders, and so greater awareness and increased intervention in this
group could have an immediate impact in a large population.
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